Andrews R K, Booth W J, Gorman J J, Castaldi P A, Berndt M C
Department of Medicine, University of Sydney, Westmead Hospital, NSW, Australia.
Biochemistry. 1989 Oct 17;28(21):8317-26. doi: 10.1021/bi00447a009.
Interaction of von Willebrand factor (vWF) with its platelet receptor only occurs in vitro in the presence of a modulator such as ristocetin. We have recently confirmed that the human platelet membrane glycoprotein (GP) Ib-IX complex is the receptor involved in the ristocetin-dependent binding of vWF by reconstitution with the purified components [Berndt, M.C., Du, X., & Booth, W.J. (1988) Biochemistry 27, 633-640]. We have now developed a similar solid-phase reconstitution assay using an alternate modulator, botrocetin, for the competitive analysis of functional domains in both vWF and the GP Ib-IX complex. Botrocetin was purified from Bothrops jararaca venom by ammonium sulfate fractionation and subsequent DEAE-cellulose and hydroxylapatite chromatography. The purified protein was a 25-kilodalton (kDa) disulfide-linked dimer with apparent subunit molecular weights of 14,000 and 14,500. Binding studies with immobilized botrocetin demonstrated that botrocetin bound to vWF and to a 52/48-kDa region of vWF that contains the GP Ib binding domain, but not to glycocalicin, a proteolytic fragment of GP Ib that contains the vWF binding site. Binding of 125I-labeled vWF to GP Ib-IX complex coated beads and to platelets was strictly botrocetin-dependent with half-maximal binding at a botrocetin concentration of congruent to 0.27 microM. Botrocetin-dependent binding of vWF was specific, saturable, and comparable to that observed with ristocetin. An anti-vWF monoclonal antibody, 3F8, inhibited ristocetin- but not botrocetin-dependent binding of vWF, suggesting the presence of distinct ristocetin and botrocetin modulator sites on vWF. The botrocetin reconstitution assay was at least an order of magnitude more sensitive than the corresponding ristocetin assay for the competitive analysis of functional domains on both vWF and the GP Ib-IX complex and has confirmed the localization of the vWF-binding domain to the 45-kDa N-terminal region of GP Ib.
血管性血友病因子(vWF)与其血小板受体的相互作用仅在体外存在诸如瑞斯托菌素等调节剂的情况下发生。我们最近证实,通过用纯化成分进行重组,人血小板膜糖蛋白(GP)Ib-IX复合物是参与vWF与瑞斯托菌素依赖性结合的受体[伯恩特,M.C.,杜,X.,& 布斯,W.J.(1988年)《生物化学》27,633 - 640]。我们现在开发了一种类似的固相重组测定法,使用另一种调节剂蛇毒因子,用于对vWF和GP Ib-IX复合物中的功能域进行竞争性分析。蛇毒因子通过硫酸铵分级分离以及随后的DEAE - 纤维素和羟基磷灰石色谱法从巴西矛头蝮蛇毒液中纯化得到。纯化后的蛋白是一种25千道尔顿(kDa)的二硫键连接二聚体,其亚基表观分子量分别为14,000和14,500。与固定化蛇毒因子的结合研究表明,蛇毒因子与vWF以及vWF中包含GP Ib结合域的52/48 - kDa区域结合,但不与糖基化纤连蛋白结合,糖基化纤连蛋白是GP Ib的一个蛋白水解片段,包含vWF结合位点。125I标记的vWF与包被有GP Ib-IX复合物的珠子以及血小板的结合严格依赖于蛇毒因子,在蛇毒因子浓度约为0.27 microM时达到半数最大结合。vWF与蛇毒因子依赖性结合具有特异性、可饱和性,并且与用瑞斯托菌素观察到的情况相当。一种抗vWF单克隆抗体3F8抑制vWF与瑞斯托菌素依赖性结合,但不抑制与蛇毒因子依赖性结合,这表明vWF上存在不同的瑞斯托菌素和蛇毒因子调节剂位点。对于vWF和GP Ib-IX复合物中功能域的竞争性分析,蛇毒因子重组测定法比相应的瑞斯托菌素测定法至少敏感一个数量级,并且已证实vWF结合域定位于GP Ib的45 - kDa N末端区域。